35 results on '"Ahmadi, Saumel"'
Search Results
2. Facilitating Structure-Function Studies of CFTR Modulator Sites with Efficiencies in Mutagenesis and Functional Screening
3. Diagnostic Yield of 2-Hour EEG Is Similar With 30-Minute EEG in Patients With a Normal 30-Minute EEG
4. Conversion of human and mouse fibroblasts into lung-like epithelial cells
5. Orkambi® and amplifier co‐therapy improves function from a rare CFTR mutation in gene‐edited cells and patient tissue
6. VX-809 and Related Corrector Compounds Exhibit Secondary Activity Stabilizing Active F508del-CFTR after Its Partial Rescue to the Cell Surface
7. Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms
8. Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia
9. High-Throughput Functional Analysis of CFTR and Other Apically Localized Proteins in iPSC-Derived Human Intestinal Organoids
10. High-throughput functional analysis of CFTR and other apically localized channels in iPSC derived intestinal organoids
11. A case of TUBB4A-related hypomyelinating leukodystrophy with abnormal movements responsive to levodopa/carbidopa (4682)
12. CHEMICAL MODULATION OF F508DEL-CFTR UNFOLDING: S8.3
13. An organoid model to assay the role of CFTR in the human epididymis epithelium
14. Augmentation of Cystic Fibrosis Transmembrane Conductance Regulator Function in Human Bronchial Epithelial Cells via SLC6A14-Dependent Amino Acid Uptake. Implications for Treatment of Cystic Fibrosis
15. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel
16. Differential Diagnosis of Pediatric Multiple Sclerosis
17. Cystic fibrosis drugs: one size does not fit all
18. Biophysical Approaches Facilitate Computational Drug Discovery for ATP-Binding Cassette Proteins
19. SLC6A14, an amino acid transporter, modifies the primary CF defect in fluid secretion
20. Author response: SLC6A14, an amino acid transporter, modifies the primary CF defect in fluid secretion
21. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del
22. Inhalational Anesthetics Induce Neuronal Protein Aggregation and Affect ER Trafficking
23. SLC6A14 Is a Genetic Modifier of Cystic Fibrosis That Regulates Pseudomonas aeruginosa Attachment to Human Bronchial Epithelial Cells
24. O rkambi® and amplifier co‐therapy improves function from a rareCFTRmutation in gene‐edited cells and patient tissue
25. SLC6A14 Enhances CFTR Channel Activity in the Cystic Fibrosis Affected Lung Epithelium
26. Directed differentiation of cholangiocytes from human pluripotent stem cells
27. Sphingosine-1-Phosphate Is a Novel Regulator of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity
28. SLC6A14 Modifies Fluid Secretory Capacity of Cystic Fibrosis Affected Epithelium by Enhancing CFTR Channel Function
29. The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylation
30. Conformational defects underlie proteasomal degradation of Dent's disease-causing mutants of ClC-5
31. Role of SLC6A14 as a Modifier of Cystic Fibrosis Phenotype
32. Functional Rescue of F508del-CFTR Using Small Molecule Correctors
33. The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylation.
34. Conformational defects underlie proteasomal degradation of Dent's disease-causing mutants of ClC-5.
35. SLC6A14Is a Genetic Modifier of Cystic Fibrosis That Regulates Pseudomonas aeruginosaAttachment to Human Bronchial Epithelial Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.